Literature DB >> 20811933

Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Cécile Gérard1, Nathalie Bleyzac, Pascal Girard, Gilles Freyer, Yves Bertrand, Michel Tod.   

Abstract

PURPOSE: Cyclosporin is administered by intermittent infusions (II) or continuous infusions (CI) to prevent acute graft-versus-host disease (aGVHD). Because cyclosporin disposition is nonlinear, organ exposure may be higher after II than after CI, but saturation of receptors must be accounted for. The aim of the study was to compare both types of administration using a mechanistic model.
METHODS: A physiologically based pharmacokinetic model was developed to estimate cyclosporin exposure and receptor occupancies (RO) in aGVHD target organs and kidneys and to compare these estimations in pediatric patients that received cyclosporin either by II or CI. The relevant biological parameters were based on a clinical study in 2 groups of pediatric patients that received cyclosporin either by II (n = 31) or CI (n = 30).
RESULTS: Simulations showed that the exposure to cyclosporin in the interstitial fluid of aGVHD target organs was greater at day 1 after II than after CI. In kidneys, the opposite order was observed. AUC(RO) in all organs was greater after CI than after II. The therapeutic index (the ratio of AUC(RO) in blood to AUC(RO) in kidneys) was greater with CI than with II.
CONCLUSIONS: CI may be slightly more favorable than II for aGVHD prevention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811933     DOI: 10.1007/s11095-010-0252-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.

Authors: 
Journal:  Pediatrics       Date:  1992-03       Impact factor: 7.124

2.  A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT.

Authors:  T Ruutu; D Niederwieser; A Gratwohl; J F Apperley
Journal:  Bone Marrow Transplant       Date:  1997-04       Impact factor: 5.483

Review 3.  Therapeutic drug monitoring for immunosuppressants.

Authors:  S H Wong
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

4.  Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Authors:  Andrea N Edginton; Walter Schmitt; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.

Authors:  M P Hendriks; N M A Blijlevens; A V M B Schattenberg; D M Burger; J P Donnelly
Journal:  Bone Marrow Transplant       Date:  2006-10       Impact factor: 5.483

6.  Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients.

Authors:  R Caruso; N Perico; D Cattaneo; G Piccinini; S Bonazzola; G Remuzzi; F Gaspari
Journal:  Clin Chem       Date:  2001-09       Impact factor: 8.327

7.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

8.  Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.

Authors:  Céline Dartois; Gilles Freyer; Mauricette Michallet; Emilie Hénin; Benoît You; Isabelle Darlavoix; Claudine Vermot-Desroches; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Review: metabolism of immunosuppressant drugs.

Authors:  Patrick Kelly; Barry D Kahan
Journal:  Curr Drug Metab       Date:  2002-06       Impact factor: 3.731

10.  Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.

Authors:  P Martin; N Bleyzac; G Souillet; C Galambrun; Y Bertrand; P H Maire; R W Jelliffe; G Aulagner
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

View more
  6 in total

Review 1.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

2.  Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.

Authors:  Nathalie Bleyzac; Michaël Philippe; Amandine Bertrand; Yves Bertrand
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

3.  Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-10-21       Impact factor: 4.200

Review 4.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  A novel perivascular cell population in the zebrafish brain.

Authors:  Marina Venero Galanternik; Daniel Castranova; Aniket V Gore; Nathan H Blewett; Hyun Min Jung; Amber N Stratman; Martha R Kirby; James Iben; Mayumi F Miller; Koichi Kawakami; Richard J Maraia; Brant M Weinstein
Journal:  Elife       Date:  2017-04-11       Impact factor: 8.140

6.  Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring.

Authors:  Sonja E Zapke; Stefan Willmann; Scott-Oliver Grebe; Kristin Menke; Petra A Thürmann; Sven Schmiedl
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.